FDA Approves sNDA for BI’s Stiolto® Respimat® | BI US
FDA approves an sNDA for STIOLTO® RESPIMAT® (tiotropium bromide & olodaterol) showing improvement in quality of life in COPD patients. View ISI, PI & Med Guide.
Search
Global Careers Page | Boehringer Ingelheim
Join a global team of more than 52,000 passionate and talented individuals dedicated to improving the health of humans and animals worldwide.
About our Innovation Prize
Established in 2015 and jointly sponsored by BI and the BI Venture Fund, the prize allows recipients to focus on development of breakthrough medicines.
US Privacy Statement
US Privacy Statement
Hurricane help: Our unwavering support of storm victims
Ensuring access to healthcare, meals, and medication for people and animals across the southeast.
Helping pets after a natural disaster in the Carolinas
Helping pets after a natural disaster in the Carolinas
U.S. FDA grants Breakthrough Therapy designation for MASH
Boehringer Ingelheim receives U.S. FDA Breakthrough Therapy designation for people living with MASH and liver fibrosis
Meet our scientist
Colleagues explain why they chose Boehringer Ingelheim
Meet the Animal Health Partnering Team
Our BD&L team talks about the team culture, why partnering is important and what they’re looking for.
Partnering Days
Partnering Days
Corporate Profile
Corporate Profile
Purchasing
Suppliers are an integral part of our success. We are passionate about solutions and new opportunities to review, improve and optimize our supplier base.
Cooking Up Change: Boehringer Cares Foundation and World Central Kitchen’s Recipe for Fighting Hunger
Our Boehringer Cares team has partnered with World Central Kitchen who aim to address the critical issue of global food insecurity.
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
Protecting Humans & Animals | COVID-19 | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's commitment to protecting both humans and animals during the COVID-19 pandemic.
First Trials of Empagliflozin in Chronic Heart Failure | Boehringer Ingelheim US
Boehringer Ingelheim and Eli Lilly and Company today announced that the EMPEROR HF (heart failure) clinical trial program was initiated.
Sustainability Matters: Carbon Neutral | Boehringer Ingelheim US
Find out more on how Boehringer Ingelheim are going carbon neutral at our manufacturing plant in Gainesville, Georgia, embracing sustainability.
A Brave New World: Digital Health Redo | Boehringer Ingelheim US
Find out more on how digital innovation in Boehringer Ingelheim is transforming the world of animal health, including disease prevention and vaccination.
Medical Affairs & Scientific Comms. | Boehringer Ingelheim US
Boehringer Ingelheim is proud to offer a 2-year, rotation-based, Fellowship program within Medical Affairs & Scientific Communications.
Boehringer Ingelheim wins 2023 Prix Galien USA
Boehringer Ingelheim wins 2023 Prix Galien USA 2023 Prix Galien USA Best Orphan/Rare Disease Solution Award
Accessibility Statement
Boehringer Ingelheim endeavors to make https://www.boehringer-ingelheim.com accessible to any and all users.
Combating The Rise of Heartworm Disease in Dogs | Boehringer Ingelheim US
Click to read more on the Boehringer Ingelheim initiative to combat the rising incidence rates of heartworm disease in dogs by over half a million.
African Swine Fever: Important Facts | Boehringer Ingelheim US
Click here to read more on the Boehringer Ingelheim efforts to understand and create a vaccine to prevent African Swine Fever in livestock across the globe.
A Few Ways We Support US Livestock | Boehringer Ingelheim US
Click here to view the Boehringer Ingelheim infographic on how we support livestock across the USA in partnership with the USDA's agriculture department.
Fighting Non-Communicable Diseases | Boehringer Ingelheim US
Read more on Boehringer Ingelheim's new NCD initiative, aiming to reduce NCD prevalence and capture the impact of our product portfolio for our patients.